transplantation

(redirected from allogeneic transplantation)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to allogeneic transplantation: tacrolimus, Autologous transplantation
References in periodicals archive ?
Donor lymphocyte infusion is the process whereby donor lymphocytes are infused to a recipient after relapse post allogeneic transplantation in an attempt to produce a graft-vs-leukemic effect and thereby eliminate malignant cells.
Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster III Time: Monday, December 9, 2013: 6:00 PM-8:00 PM Location: Hall G (Ernest N.
The research team acknowledged that their analysis might be considered flawed, since only 54% of the patients assigned to autologous transplantation actually received the therapy compared with 81% of those assigned to allogeneic transplantation and 91% of those assigned to chemotherapy.
Moreover, it enables the use of a mismatched, related (haplo-identical) donor, thus providing virtually everyone with an immediately available donor and treatment, thereby addressing a high unmet medical need as patients eligible for an allogeneic transplantation but without a matched donor available in general have no treatment options left.
Non-myeloablative allogeneic transplantation (NMAT) can provide prolonged remissions in patients with advanced B-cell lymphoma via the graft versus lymphoma effect, though patients and donors need to be carefully selected.
These results justify the systematic collection of cord blood in families with a child affected by a disease that can be treated successfully by allogeneic transplantation of hematopoietic stem cells," wrote Vanderson Rocha, MD and colleagues from the Eurocord-Cord Blood Transplant Group.
Our study addresses this unanswered question and shows that the toxicity of allogeneic transplantation outweighed the benefits of the reduced relapse risk in patients with standard-risk myeloma.
Cellerant's proprietary cell-based therapeutic technology is the basis for future commercial applications in allogeneic transplantation, stem cell expansion, protein pharmaceuticals and T-cell therapy.
The Eligix(TM) CD8-DLI Cell Separation System is intended for ex vivo use for patients receiving a donor leukocyte infusion (DLI) following allogeneic transplantation to augment immune response against malignancies.
Cellerant's proprietary HSC technology is the basis for future commercial applications in allogeneic transplantation, stem cell expansion, protein pharmaceuticals and T-cell therapy.